{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:16:26Z","timestamp":1781842586983,"version":"3.54.5"},"reference-count":81,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pulmonary exacerbations (PExs) are events in the course of bronchiectasis which are defined as an increase in disease symptoms lasting a period of a few days. It is established that the tendency toward having PEx is stable throughout the course of the disease. Certain conditions were found to be associated with an increased risk of developing a PEx. Among these are chronic airway infection with Pseudomonas aeruginosa or Aspergillus species, concomitant airway diseases (asthma, chronic obstructive pulmonary disease, and chronic rhinosinusitis), genetic factors such as primary ciliary dyskinesia, and nutritional factors. The immediate events underlying the onset of a PEx are less clearly determined. Although acute changes in bacterial airway composition have been the paradigm for decades, recent microbiome-focused research has not uniformly established such acute changes at the onset of PEx. Other acute changes such as air pollution, viral infection, and changes in bacterial metabolic activity have also been implicated as causes of a PEx. Despite these gaps in our knowledge of the biology of PEx, antimicrobial therapy directed against the identified pathogens in sputum is currently the recommended therapeutic strategy. Various long-term therapies, including antimicrobial and anti-inflammatory strategies, have been proven effective in reducing the frequency of PEx, leading to a recommendation for the use of these strategies in people with frequent PEx.<\/jats:p>","DOI":"10.1055\/s-0041-1730944","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T22:34:05Z","timestamp":1626302045000},"page":"595-605","source":"Crossref","is-referenced-by-count":7,"title":["Bronchiectasis Exacerbations: Definitions, Causes, and Acute Management"],"prefix":"10.1055","volume":"42","author":[{"given":"Sivan","family":"Perl","sequence":"additional","affiliation":[{"name":"Pulmonology Institute, Shamir Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Shteinberg","sequence":"additional","affiliation":[{"name":"Pulmonology Institute and CF Center, Carmel Medical Center, Technion\u2014Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1183\/09031936.00026313","article-title":"Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score","volume":"43","author":"M\u00c1 Mart\u00ednez-Garc\u00eda","year":"2014","journal-title":"Eur Respir J"},{"issue":"05","key":"ref2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","article-title":"The bronchiectasis severity index: an international derivation and validation study","volume":"189","author":"J D Chalmers","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0954-6111(93)90072-8","article-title":"Effect of antibiotics on sputum inflammatory contents in acute exacerbations of bronchiectasis","volume":"87","author":"M Ip","year":"1993","journal-title":"Respir Med"},{"issue":"08","key":"ref4","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.4187\/respcare.04004","article-title":"Inflammatory responses, spirometry, and quality of life in subjects with bronchiectasis exacerbations","volume":"60","author":"W-J Guan","year":"2015","journal-title":"Respir Care"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/1479972308091823","article-title":"Quality of life and inflammation in exacerbations of bronchiectasis","volume":"5","author":"J M Courtney","year":"2008","journal-title":"Chron Respir Dis"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jinf.2018.04.006","article-title":"Pneumonic and non-pneumonic exacerbations in bronchiectasis: clinical and microbiological differences","volume":"77","author":"E Polverino","year":"2018","journal-title":"J Infect"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"1700051","DOI":"10.1183\/13993003.00051-2017","article-title":"Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research","volume":"49","author":"A T Hill","year":"2017","journal-title":"Eur Respir J"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.arbr.2017.07.014","article-title":"Spanish guidelines on treatment of bronchiectasis in adults","volume":"54","author":"M\u00c1 Mart\u00ednez-Garc\u00eda","year":"2018","journal-title":"Arch Bronconeumol"},{"issue":"S 01","key":"ref9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/thoraxjnl-2018-212463","article-title":"British Thoracic Society Guideline for bronchiectasis in adults","volume":"74","author":"A T Hill","year":"2019","journal-title":"Thorax"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"1701953","DOI":"10.1183\/13993003.01953-2017","article-title":"The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis","volume":"51","author":"D Ara\u00fajo","year":"2018","journal-title":"Eur Respir J"},{"issue":"07","key":"ref11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","article-title":"Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis","volume":"186","author":"J D Chalmers","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1183\/09031936.00122508","article-title":"Assessing response to treatment of exacerbations of bronchiectasis in adults","volume":"33","author":"M P Murray","year":"2009","journal-title":"Eur Respir J"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1164\/rccm.201210-1937OC","article-title":"Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation","volume":"187","author":"M M Tunney","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"e0170622","DOI":"10.1371\/journal.pone.0170622","article-title":"Longitudinal assessment of sputum microbiome by sequencing of the 16S rRNA gene in non-cystic fibrosis bronchiectasis patients","volume":"12","author":"M J Cox","year":"2017","journal-title":"PLoS One"},{"issue":"08","key":"ref15","doi-asserted-by":"crossref","first-page":"e0183553","DOI":"10.1371\/journal.pone.0183553","article-title":"Differences of lung microbiome in patients with clinically stable and exacerbated bronchiectasis","volume":"12","author":"M K Byun","year":"2017","journal-title":"PLoS One"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"e00292-20","DOI":"10.1128\/mSystems.00292-20","article-title":"High-resolution longitudinal dynamics of the cystic fibrosis sputum microbiome and metabolome through antibiotic therapy","volume":"5","author":"R Raghuvanshi","year":"2020","journal-title":"mSystems"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/ismej.2013.232","article-title":"Metabolite transfer with the fermentation product 2,3-butanediol enhances virulence by Pseudomonas aeruginosa","volume":"8","author":"A Venkataraman","year":"2014","journal-title":"ISME J"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1038\/ismej.2016.76","article-title":"The fermentation product 2,3-butanediol alters P. aeruginosa clearance, cytokine response and the lung microbiome","volume":"10","author":"M Nguyen","year":"2016","journal-title":"ISME J"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1164\/rccm.201505-0943OC","article-title":"Short-chain fatty acids cause an IL-8 response in cystic fibrosis airways via increased GPR41","volume":"192","author":"B Mirkovi\u0107","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/ismej.2014.234","article-title":"A Winogradsky-based culture system shows an association between microbial fermentation and cystic fibrosis exacerbation","volume":"9","author":"R A Quinn","year":"2015","journal-title":"ISME J"},{"issue":"06","key":"ref21","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1378\/chest.14-1961","article-title":"The role of viral infection in pulmonary exacerbations of bronchiectasis in adults: a prospective study","volume":"147","author":"Y-H Gao","year":"2015","journal-title":"Chest"},{"issue":"153","key":"ref22","doi-asserted-by":"crossref","first-page":"190048","DOI":"10.1183\/16000617.0048-2019","article-title":"The microbiome in bronchiectasis","volume":"28","author":"H Richardson","year":"2019","journal-title":"Eur Respir Rev"},{"issue":"10","key":"ref23","first-page":"621","article-title":"The roles of bacteria and viruses in bronchiectasis exacerbation: a prospective study","volume":"56","author":"C-L Chen","year":"2020","journal-title":"Arch Bronconeumol"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12890-018-0636-2","article-title":"Viruses in bronchiectasis: a pilot study to explore the presence of community acquired respiratory viruses in stable patients and during acute exacerbations","volume":"18","author":"A B Mitchell","year":"2018","journal-title":"BMC Pulm Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/978-3-319-61452-6_15","volume-title":"Exacerbation of bronchiectasis","author":"E Polverino","year":"2018"},{"key":"ref26","first-page":"PA364","article-title":"The impact of acute air pollution fluctuations on non-cystic fibrosis bronchiectasis pulmonary exacerbations: a case-crossover analysis","author":"P Goeminne","year":"2015","journal-title":"Eur Respir J"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"1702557","DOI":"10.1183\/13993003.02557-2017","article-title":"The impact of acute air pollution fluctuations on bronchiectasis pulmonary exacerbation: a case-crossover analysis","volume":"52","author":"P C Goeminne","year":"2018","journal-title":"Eur Respir J"},{"issue":"07","key":"ref28","first-page":"257","article-title":"Association between environmental factors and hospitalisations for bronchiectasis in Badalona, Barcelona, Spain (2007-2015)","volume":"150","author":"I Garcia-Oliv\u00e9","year":"2018","journal-title":"Med Clin (Barc)"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2147\/COPD.S231317","article-title":"Acute effects of air pollution on hospital admissions for asthma, COPD, and bronchiectasis in Ahvaz, Iran","volume":"15","author":"H Raji","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12931-014-0108-z","article-title":"Impact of traffic related air pollution indicators on non-cystic fibrosis bronchiectasis mortality: a cohort analysis","volume":"15","author":"P C Goeminne","year":"2014","journal-title":"Respir Res"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1183\/13993003.01390-2015","article-title":"Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia","volume":"47","author":"F Ratjen","year":"2016","journal-title":"Eur Respir J"},{"issue":"10","key":"ref32","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1164\/rccm.201605-1027OC","article-title":"Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis","volume":"195","author":"J D Chalmers","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"08","key":"ref33","doi-asserted-by":"crossref","first-page":"E2631","DOI":"10.3390\/jcm9082631","article-title":"Systemic inflammation during and after bronchiectasis exacerbations: impact of Pseudomonas aeruginosa","volume":"9","author":"R Men\u00e9ndez","year":"2020","journal-title":"J Clin Med"},{"issue":"09","key":"ref34","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/nm.2847","article-title":"Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo","volume":"18","author":"B G Yipp","year":"2012","journal-title":"Nat Med"},{"issue":"11","key":"ref36","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1164\/rccm.201711-2202OC","article-title":"Characterization of the \u201cfrequent exacerbator phenotype\u201d in bronchiectasis","volume":"197","author":"J D Chalmers","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"1800766","DOI":"10.1183\/13993003.00766-2018","article-title":"Immunological corollary of the pulmonary mycobiome in bronchiectasis: the CAMEB study","volume":"52","author":"M Mac Aog\u00e1in","year":"2018","journal-title":"Eur Respir J"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"642503","DOI":"10.1155\/2015\/642503","article-title":"Neutrophilic bronchial inflammation correlates with clinical and functional findings in patients with noncystic fibrosis bronchiectasis","volume":"2015","author":"F L Dente","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"09","key":"ref39","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/thoraxjnl-2018-212895","article-title":"Antimicrobial peptides, disease severity and exacerbations in bronchiectasis","volume":"74","author":"O Sibila","year":"2019","journal-title":"Thorax"},{"issue":"06","key":"ref40","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1183\/13993003.01862-2015","article-title":"Asthma and bronchiectasis exacerbation","volume":"47","author":"B Mao","year":"2016","journal-title":"Eur Respir J"},{"issue":"12","key":"ref41","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S2213-2600(16)30320-4","article-title":"Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study","volume":"4","author":"M J McDonnell","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"00115-2017","DOI":"10.1183\/23120541.00115-2017","article-title":"Upper airway involvement in bronchiectasis is marked by early onset and allergic features","volume":"4","author":"M Shteinberg","year":"2018","journal-title":"ERJ Open Res"},{"issue":"07","key":"ref43","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.rmed.2013.04.006","article-title":"Symptoms of airway reflux predict exacerbations and quality of life in bronchiectasis","volume":"107","author":"P Mandal","year":"2013","journal-title":"Respir Med"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2019.01.009","article-title":"Vitamin D and disease severity in bronchiectasis","volume":"148","author":"S Ferri","year":"2019","journal-title":"Respir Med"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"i6583","DOI":"10.1136\/bmj.i6583","article-title":"Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data","volume":"356","author":"A R Martineau","year":"2017","journal-title":"BMJ"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/thoraxjnl-2012-202125","article-title":"Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis","volume":"68","author":"J D Chalmers","year":"2013","journal-title":"Thorax"},{"issue":"04","key":"ref47","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1172\/JCI6861","article-title":"Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis","volume":"104","author":"P Garred","year":"1999","journal-title":"J Clin Invest"},{"issue":"03","key":"ref48","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S2213-2600(13)70001-8","article-title":"Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study","volume":"1","author":"J D Chalmers","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"04","key":"ref49","doi-asserted-by":"crossref","first-page":"e0215051","DOI":"10.1371\/journal.pone.0215051","article-title":"Undetectable mannose binding lectin is associated with HRCT proven bronchiectasis in rheumatoid arthritis (RA)","volume":"14","author":"K Makin","year":"2019","journal-title":"PLoS One"},{"issue":"05","key":"ref50","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/ppul.24711","article-title":"Impact of mannose-binding lectin 2 gene polymorphisms on disease severity in noncystic fibrosis bronchiectasis in children","volume":"55","author":"D Dogru","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"02","key":"ref51","first-page":"145","article-title":"The clinical features of bronchiectasis associated with alpha-1 antitrypsin deficiency, common variable immunodeficiency and primary ciliary dyskinesia--results from the U.S. Bronchiectasis Research Registry","volume":"6","author":"E Eden","year":"2019","journal-title":"Chronic Obstr Pulm Dis (Miami)"},{"issue":"04","key":"ref52","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/thoraxjnl-2016-208775","article-title":"FUT2 genotype influences lung function, exacerbation frequency and airway microbiota in non-CF bronchiectasis","volume":"72","author":"S L Taylor","year":"2017","journal-title":"Thorax"},{"issue":"03","key":"ref53","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1513\/AnnalsATS.201706-488OC","article-title":"Cardiovascular outcomes after a respiratory tract infection among adults with non-cystic fibrosis bronchiectasis: a general population-based study","volume":"15","author":"V Navaratnam","year":"2018","journal-title":"Annals Am Thoracic Soc"},{"issue":"03","key":"ref54","doi-asserted-by":"crossref","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"E Polverino","year":"2017","journal-title":"Eur Respir J"},{"issue":"154","key":"ref55","doi-asserted-by":"crossref","first-page":"190055","DOI":"10.1183\/16000617.0055-2019","article-title":"The biology of pulmonary exacerbations in bronchiectasis","volume":"28","author":"F Amati","year":"2019","journal-title":"Eur Respir Rev"},{"key":"ref56","first-page":"CD012579","article-title":"Oral versus inhaled antibiotics for bronchiectasis","volume":"3","author":"S Spencer","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"ref57","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1080\/09593985.2019.1579286","article-title":"Effect of airway clearance techniques in patients experiencing an acute exacerbation of bronchiectasis: a systematic review","volume":"36","author":"J Phillips","year":"2020","journal-title":"Physiother Theory Pract"},{"issue":"01","key":"ref58","first-page":"CD007525","article-title":"Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis","author":"S J Pizzutto","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"09","key":"ref59","doi-asserted-by":"crossref","first-page":"e02761-16","DOI":"10.1128\/AAC.02761-16","article-title":"The nonantibiotic macrolide EM703 improves survival in a model of quinolone-treated Pseudomonas aeruginosa airway infection","volume":"61","author":"G Kasetty","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"02","key":"ref60","doi-asserted-by":"crossref","first-page":"e000407","DOI":"10.1136\/bmjopen-2011-000407","article-title":"Inhaled hypertonic saline in adults hospitalised for exacerbation of cystic fibrosis lung disease: a retrospective study","volume":"2","author":"A A Pezzulo","year":"2012","journal-title":"BMJ Open"},{"issue":"12","key":"ref61","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.rmed.2011.07.019","article-title":"Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis","volume":"105","author":"F Kellett","year":"2011","journal-title":"Respir Med"},{"issue":"05","key":"ref62","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.rmed.2011.12.021","article-title":"The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis","volume":"106","author":"C HH Nicolson","year":"2012","journal-title":"Respir Med"},{"issue":"01","key":"ref63","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12931-019-1042-x","article-title":"Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial","volume":"20","author":"Q Qi","year":"2019","journal-title":"Respir Res"},{"issue":"12","key":"ref64","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/thoraxjnl-2014-205587","article-title":"Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial","volume":"69","author":"D Bilton","year":"2014","journal-title":"Thorax"},{"issue":"05","key":"ref65","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1378\/chest.113.5.1329","article-title":"Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group","volume":"113","author":"A E O'Donnell","year":"1998","journal-title":"Chest"},{"issue":"04","key":"ref66","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s11096-012-9659-6","article-title":"Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis","volume":"34","author":"R Hernando","year":"2012","journal-title":"Int J Clin Pharm"},{"issue":"09","key":"ref67","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.rmed.2005.12.002","article-title":"Inhaled steroids improve quality of life in patients with steady-state bronchiectasis","volume":"100","author":"M A Mart\u00ednez-Garc\u00eda","year":"2006","journal-title":"Respir Med"},{"key":"ref68","first-page":"CD000996","article-title":"Inhaled corticosteroids for bronchiectasis","volume":"5","author":"N Kapur","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"106127","DOI":"10.1016\/j.rmed.2020.106127","article-title":"Role of inhaled corticosteroids in reducing exacerbations in bronchiectasis patients with blood eosinophilia pooled post-hoc analysis of 2 randomized clinical trials","volume":"172","author":"M A Martinez-Garcia","year":"2020","journal-title":"Respir Med"},{"key":"ref70","first-page":"PA360","article-title":"Atorvastatin as an anti inflammatory in bronchiectasis","author":"P Bedi","year":"2015","journal-title":"Eur Respin J"},{"issue":"12","key":"ref71","doi-asserted-by":"crossref","first-page":"E517","DOI":"10.3390\/jcm7120517","article-title":"Mucolytic agents and statins use is associated with a lower risk of acute exacerbations in patients with bronchiectasis-chronic obstructive pulmonary disease overlap","volume":"7","author":"V Y-F Su","year":"2018","journal-title":"J Clin Med"},{"issue":"08","key":"ref72","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.201312-2208OC","article-title":"Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection","volume":"189","author":"C S Haworth","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"01","key":"ref73","doi-asserted-by":"crossref","first-page":"1702052","DOI":"10.1183\/13993003.02052-2017","article-title":"RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"A De Soyza","year":"2018","journal-title":"Eur Respir J"},{"issue":"03","key":"ref74","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"C S Haworth","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"04","key":"ref75","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.201005-0756OC","article-title":"A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis","volume":"183","author":"M P Murray","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/1874306401509010030","article-title":"Evidence of inhaled tobramycin in non-cystic fibrosis bronchiectasis","volume":"9","author":"M Vendrell","year":"2015","journal-title":"Open Respir Med J"},{"issue":"12","key":"ref77","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial","volume":"309","author":"D J Serisier","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"ref78","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"J Altenburg","year":"2013","journal-title":"JAMA"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"C Wong","year":"2012","journal-title":"Lancet"},{"key":"ref80","first-page":"1479972318790269","article-title":"Azithromycin or erythromycin? Macrolides for non-cystic fibrosis bronchiectasis in adults: a systematic review and adjusted indirect treatment comparison","volume":"16","author":"W Li","year":"2019","journal-title":"Chron Respir Dis"},{"issue":"10","key":"ref81","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-2600(19)30191-2","article-title":"Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis","volume":"7","author":"J D Chalmers","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"22","key":"ref82","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"J D Chalmers","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1730944.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T22:48:23Z","timestamp":1626302903000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1730944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":81,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2021,7,14]]},"published-print":{"date-parts":[[2021,8]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1730944","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]}}}